Hot or Not, Stock Market Edition: 02/19/2026
Happy Thursday. Here are the stock stories we're following today:
- Hot: Semiconductor packaging specialist Amkor Technology (AMKR) is gaining momentum; healthcare heavyweight HCA Healthcare (HCA) is heating up
- Not: Biotech player Arcus Biosciences (RCUS) is feeling the freeze; bitcoin miner CleanSpark (CLSK) is losing steam
P.S. Speaking of hot — have you checked out our latest video about 5 Stocks to Buy Heavy Before March 2026?
A note from our sponsors...
The 10 Best AI Stocks to Own NOW-Yours FREE If you've been following the AI revolution, there's a chance you can guess who's #1 on my brand new list of the best AI stocks to own (if you are lucky, you may even own some shares of this powerhouse already). But I doubt you can guess who's #3 on the list. (HINT: It delivers a technology that's critical to the AI revolution and will soon be embedded in countless consumer products.) Learn the names of all 10 stocks here. FREE.🔥 HOT: Healthcare heavyweight HCA Healthcare (HCA) is heating up, climbing 15% in the past month. Why? A few reasons: 1) The hospital operator continues topping earnings expectations while maintaining robust cash generation — a rare feat in an industry facing reimbursement pressures. 2) Shares have surged 68% over the past year and are up 7% just this past week, with institutional investors cheering the sustained operational performance. 3) The stock holds a Zen Rating of B (Buy) placing it in the top 20% of all stocks we track. It scores particularly well with a B Grade for Financials, Momentum, Safety, and Sentiment. The bottom line? Buy. HCA's cash-producing power and consistent execution make it a compelling long-term healthcare hold, even as the sector faces regulatory uncertainty.
🥶 NOT: Biotech player Arcus Biosciences (RCUS) is feeling serious buzzkill after a fresh wave of analyst downgrades. Wells Fargo downgraded RCUS from Overweight to Equal-Weight and slashed its price target from $30 to $23, sending shares tumbling. That’s not all the bad news — the stock has declined 10% over the past month as investor enthusiasm for its pipeline cooled, despite a 75% gain in the past year that's now at risk. 3) The stock holds a Zen Rating of D (Sell) placing it in the lower tiers of stocks we track. It struggles with a D Grade for Financials, Growth, Safety, and Zen Rating overall, reflecting weak fundamentals across the board. The verdict? With analyst support eroding and poor scores on key metrics, there are better places to park your biotech dollars right now.
🔥 HOT: Semiconductor packaging specialist Amkor Technology (AMKR) is gaining momentum, trading near its 52-week high. What's behind the move? Three things: 1) The company's Q4 earnings crushed Wall Street expectations, with robust demand in advanced packaging and data center computing driving the upside — CEO Kevin Engel noted that "all end markets exceeded expectations, with the largest upside coming from communications, driven by iOS devices." 2) The stock is riding strong technical tailwinds, up over 100% over the past year as investors pile into advanced semiconductor packaging plays. 3) The stock holds a Zen Rating of B (Buy), meaning it currently ranks in the top 20% of stocks based on a 115-factor review. It scores particularly well with an A Grade for Sentiment and a B Grade for Momentum and Safety. The verdict? Despite trading near highs, AMKR's advanced packaging capabilities and data center exposure position it well for continued momentum. (P.S. For more hot stocks in the AI space, check this out.)
🥶 NOT: Bitcoin miner CleanSpark (CLSK) is losing steam, down 27% in the past month as crypto volatility takes its toll. What's going on? 1) The stock tumbled 7% in the past week alone, alongside Bitcoin's drop below $68,000, with crypto-linked equities getting hammered harder than the underlying digital assets. 2) Despite brief Friday rallies when Bitcoin bounced above $69,000, CLSK has shed significant value in recent months as investors rotate out of crypto mining plays. 3) The stock holds a Zen Rating of F (Strong Sell), ranking it at the very bottom of all stocks. It struggles with an F Grade for Safety, Sentiment, and Zen Rating, plus a D Grade for Financials and Value. The bottom line? CLSK is one of the most heavily shorted stocks in the market, and with Bitcoin volatility showing no signs of calming, this crypto miner faces an uphill battle.
What to Do Next?
Want to get in touch? Email us at news@wallstreetzen.com.
Keep Reading
See All News
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.